FDA Approvals in Oncology: July-September 2024
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
Based on estimates from the National Cancer Institute, in 2023, more than 110,000 cases of gynecologic cancers are expected...